Skip to main content

Table 3 Summary of adverse events related to treatment with at least 10% incidence—by cohort

From: Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases

  Overall Cohort
HER2-negative (N = 9) HER2-positive (N = 29)
Grade Grade
N 1 2 3 1 2 3 4
AE name
Hemoglobin 29 (76%) 4 (44%) 3(33%)   10 (34%) 11 (38%) 1 (3%)  
Fatigue 28 (74%) 1 (11%) 3(33%) 2(22%) 9 (31%) 9 (31%) 4 (14%)  
Platelets 28 (74%) 3 (33%) 3(33%)   6 (21%) 12 (41%) 3 (10%) 1 (3%)
AST 23 (61%) 5 (56%) 1(11%)   15 (52%)   2 (7%)  
  22 (58%) 2 (22%) 1(11%)   3 (10%) 13 (45%) 3 (10%)  
Head/headache 20 (53%) 4 (44%)    10 (34%) 6 (21%)   
Hyperglycemia 18 (47%) 3 (33%) 1(11%)   12 (41%) 2 (7%)   
Leukocytes 18 (47%)     4 (14%) 14   
Nausea 17 (45%) 1 (11%) 1(11%)   13 (45%) 2 (7%)   
ALT 14 (37%) 3 (33%) 1(11%)   8 (28%)   2 (7%)  
Constipation 14 (37%) 3(33%) 1(11%)   7 (24%) 3 (10%)   
Neuropathy-sensory 14 (37%) 3(33%)    9 (31%) 2 (7%)   
Nose, hemorrhage 12 (32%) 1(11%)    9 (31%) 2 (7%)   
Alkaline phosphatase 11 (29%)     9 (31%) 2 (7%)   
Diarrhea w/o prior colostomy 11 (29%) 1(11%) 1(11%)   7 (24%) 2 (7%)   
Cough 9 (24%)     8 (28%) 1 (3%)   
Hypertension 9 (24%)     6 (21%) 2 (7%) 1 (3%)  
Alteration in bone age 8 (21%)     6 (21%) 2 (7%)   
Proteinuria 8 (21%) 1(11%)    6 (21%) 1 (3%)   
Extremity-limb, pain 7 (18%)     4 (14%) 2 (7%) 1 (3%)  
Alopecia 6 (16%)   1(11%)    4 (14%) 1 (3%)  
Hyponatremia 6 (16%)     5 (17%)   1 (3%)  
Joint, pain 6 (16%)     3 (10%) 2 (7%) 1 (3%)  
Vomiting 6 (16%) 2(22%) 1(11%)   2 (7%) 1 (3%)   
Allergic reaction 5 (13%)     1 (3%) 4 (14%)   
Back, pain 5 (13%)     4 (14%) 1 (3%)   
Dizziness 5 (13%)     2 (7%) 3 (10%)   
Infection Grade 0–2, upper airway 5 (13%)     4 (14%) 1 (3%)   
Left ventricular systolic dysfunction 5 (13%)      5 (17%)   
Pain-other 5 (13%) 1(11%) 1(11%)   1 (3%) 2 (7%)   
Rectum, hemorrhage 5 (13%)     4 (14%) 1 (3%)   
Bone, pain 4 (11%)     4 (14%)    
CNS, hemorrhage 4 (11%) 1(11%) 1(11%)   2 (7%)    
Constitutional, other 4 (11%)     3 (10%) 1 (3%)   
Creatinine 4 (11%) 2(22%)    2 (7%)    
GI-other 4 (11%)     4 (14%)    
Hypocalcemia 4 (11%)     4 (14%)    
Hypokalemia 4 (11%) 1(11%)    3 (10%)    
Metabolic/laboratory-other 4 (11%) 2(22%) 1(11%)   1 (3%)    
Skin-other 4 (11%) 2(22%)    1 (3%) 1 (3%)   
Throat/pharynx/larynx, pain 4 (11%)     4 (14%)    
  1. Abbreviations: AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase, CNS central nervous system, GI gastrointestinal, HER2 human epidermal growth factor receptor 2